Your browser doesn't support javascript.
loading
Recruitment of FBXO22 for targeted degradation of NSD2.
Nie, David Y; Tabor, John R; Li, Jianping; Kutera, Maria; St-Germain, Jonathan; Hanley, Ronan P; Wolf, Esther; Paulakonis, Ethan; Kenney, Tristan M G; Duan, Shili; Shrestha, Suman; Owens, Dominic D G; Maitland, Matthew E R; Pon, Ailing; Szewczyk, Magdalena; Lamberto, Anthony Joseph; Menes, Michael; Li, Fengling; Penn, Linda Z; Barsyte-Lovejoy, Dalia; Brown, Nicholas G; Barsotti, Anthony M; Stamford, Andrew W; Collins, Jon L; Wilson, Derek J; Raught, Brian; Licht, Jonathan D; James, Lindsey I; Arrowsmith, Cheryl H.
Afiliación
  • Nie DY; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Tabor JR; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Li J; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Kutera M; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • St-Germain J; University of Florida Health Cancer Center, Gainesville, FL, USA.
  • Hanley RP; Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Wolf E; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Paulakonis E; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Kenney TMG; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Duan S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Shrestha S; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Owens DDG; C4 Therapeutics, Watertown, MA, USA.
  • Maitland MER; Department of Chemistry, York University, Toronto, Ontario, Canada.
  • Pon A; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.
  • Szewczyk M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Lamberto AJ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Menes M; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Penn LZ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Barsyte-Lovejoy D; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Brown NG; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Barsotti AM; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Stamford AW; Amphista Therapeutics, Cambridge, UK.
  • Collins JL; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Wilson DJ; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Raught B; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
  • Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA.
  • James LI; University of Florida Health Cancer Center, Gainesville, FL, USA.
  • Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
Nat Chem Biol ; 2024 Jul 04.
Article en En | MEDLINE | ID: mdl-38965384
ABSTRACT
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins for proteasomal degradation. Here we describe a TPD strategy involving the recruitment of FBXO22 to induce degradation of the histone methyltransferase and oncogene NSD2. UNC8732 facilitates FBXO22-mediated degradation of NSD2 in acute lymphoblastic leukemia cells harboring the NSD2 gain-of-function mutation p.E1099K, resulting in growth suppression, apoptosis and reversal of drug resistance. The primary amine of UNC8732 is metabolized to an aldehyde species, which engages C326 of FBXO22 to recruit the SCFFBXO22 Cullin complex. We further demonstrate that a previously reported alkyl amine-containing degrader targeting XIAP is similarly dependent on SCFFBXO22. Overall, we present a potent NSD2 degrader for the exploration of NSD2 disease phenotypes and a new FBXO22-recruitment strategy for TPD.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Chem Biol Asunto de la revista: BIOLOGIA / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nat Chem Biol Asunto de la revista: BIOLOGIA / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Canadá